(ABOS) Acumen Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00509G2093
ABOS: Alzheimer's, Immunotherapy, Amyloid-Beta, Oligomers
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company specializing in the development of targeted therapies for Alzheimers disease. The companys lead candidate, sabirnetug (ACU193), is a recombinant humanized immunoglobulin gamma 2 designed to target soluble amyloid-beta oligomers, which are implicated in the progression of Alzheimers. Sabirnetug has completed Phase I clinical trials, demonstrating its potential as an immunotherapy for this debilitating neurodegenerative disorder.
Acumen has established strategic partnerships to advance its pipeline. A license agreement with Lonza Sales AG ensures the manufacturing and commercialization of sabirnetug, while a collaboration with Halozyme, Inc. focuses on developing a subcutaneous formulation of the drug, enhancing patient accessibility. Incorporated in 1996 and headquartered in Charlottesville, Virginia, Acumen is positioned as a specialized player in the Alzheimers therapeutic landscape.
From a technical perspective, ABOS is currently trading at $1.23 with a 20-day average volume of 243,782 shares. The stock is below its 20-day SMA of $1.36 and 50-day SMA of $1.56, signaling near-term downward momentum. However, the 200-day SMA of $2.38 indicates longer-term weakness. The ATR of 0.11 reflects relatively low volatility.
Fundamentally, Acumens market cap stands at $76.90M with a price-to-book ratio of 0.35, suggesting modest valuation relative to book value. The price-to-sales ratio of 538.78 highlights investor expectations for future revenue growth despite current losses, as indicated by a return on equity of -37.60%.
3-Month Forecast Based onAdditional Sources for ABOS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ABOS Stock Overview
Market Cap in USD | 75m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2021-07-01 |
ABOS Stock Ratings
Growth 5y | -79.9% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -66.7 |
Analysts | 4.83/5 |
Fair Price Momentum | 0.69 USD |
Fair Price DCF | - |
ABOS Dividends
No Dividends PaidABOS Growth Ratios
Growth Correlation 3m | -96.4% |
Growth Correlation 12m | -86.2% |
Growth Correlation 5y | -82.1% |
CAGR 5y | -52.64% |
CAGR/Max DD 5y | -0.56 |
Sharpe Ratio 12m | -2.69 |
Alpha | -90.27 |
Beta | 2.60 |
Volatility | 82.56% |
Current Volume | 155k |
Average Volume 20d | 188.1k |
As of March 16, 2025, the stock is trading at USD 1.26 with a total of 154,985 shares traded.
Over the past week, the price has changed by +0.80%, over one month by -13.10%, over three months by -36.04% and over the past year by -69.19%.
No, based on ValueRay Analyses, Acumen Pharmaceuticals (NASDAQ:ABOS) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -79.94 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABOS as of March 2025 is 0.69. This means that ABOS is currently overvalued and has a potential downside of -45.24%.
Acumen Pharmaceuticals has received a consensus analysts rating of 4.83. Therefor, it is recommend to buy ABOS.
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ABOS Acumen Pharmaceuticals will be worth about 0.8 in March 2026. The stock is currently trading at 1.26. This means that the stock has a potential downside of -38.1%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 10.8 | 757.1% |
Analysts Target Price | 10.8 | 757.1% |
ValueRay Target Price | 0.8 | -38.1% |